NCCN Guidelines® Recommend SIR-Spheres® Y-90 Resin microspheres for the Treatment of Metastatic Colorectal Cancer

December 12, 2016 09:00 AM Eastern Standard Time WOBURN, Mass.–(BUSINESS WIRE)–Sirtex Medical Limited (ASX: SRX) today announced that SIR-Spheres® Y-90 resin microspheres has been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. This designation denotes that there…

Details